Perioperative antiplatelet use is not associated with increased risk of mortality among older adults undergoing operative hip fracture repair

Objectives: To assess whether perioperative antiplatelet use increases mortality risk among older adults undergoing operative hip fracture repair. Design: Retrospective study. Setting: Level 1 trauma center. Patient Selection Criteria: A total of 965 patients 65 years or older who underwent surgical fixation for hip fractures (OTA/OA 31A, 31B and 31C) between 2018 and 2023. Outcome Measures and Comparisons: The primary outcome was mortality at 365 days after discharge. Secondary outcomes were mortality at 30 days and 90 days, length of stay (LOS) > 7 days, need for blood transfusion, and 30-day readmission. Statistical Methods: Multivariate Cox proportional hazards models assessed the association between antiplatelet use and mortality. For secondary outcomes, a Firth penalized logistic regression model was used, correcting for potential confounders. RESULTS: The use of antiplatelet medications perioperatively was not significantly associated with mortality at 365 days, with adjusted hazard ratio (aHR) of 1.17, 95% confidence interval (CI) [0.76, 1.79] or at 30 days and 90 days, with aHRs of 0.94, 95% CI [0.44, 2.00] and 1.03, 95% CI [0.54, 1.97], respectively. There was a higher odds of being readmitted within 30 days of hospital discharge and getting a transfusion, with adjusted odds ratios (aORs) of 1.83, 95% CI [1.12, 3.00] and 1.60, 95% CI [1.00, 2.56], respectively, whereas there was no significant association with length of stay greater than 7 days, with aOR of 0.84, 95% CI [0.56, 1.26]. Conclusion: These findings indicate that undergoing hip fracture repair while on antiplatelet medications does not appear to confer a higher risk of mortality but may be correlated to higher readmission or transfusion rates. Level of Evidence: Therapeutic Level III.

Authors

Institutions

Publication Details

Journal
OTA International The Open Access Journal of Orthopaedic Trauma
Published
2026-11-16
DOI
https://doi.org/10.1097/oi9.0000000000000538
Primary Topic
Hip and Femur Fractures
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Perioperative antiplatelet use is not associated with increased risk of mortality among older adults undergoing operative hip fracture repair

Catherine Desroches, Amy Steele, Michael Akodu, Karen Chahal et al.
1 links
OTA International The Open Access Journal of Orthopaedic Trauma
Hip and Femur Fractures
article

Perioperative antiplatelet use is not associated with increased risk of mortality among older adults undergoing operative hip fracture repair

Catherine Desroches, Amy Steele, Michael Akodu, Karen Chahal, Diviya Rajesh, Cancan Zhang, Naing Aung, Michael McTague, Paul Appleton, Daniele Olveczky, John Wixted, Edward Rodriguez, Kiran Agarwal-Harding
article en

Abstract

Objectives: To assess whether perioperative antiplatelet use increases mortality risk among older adults undergoing operative hip fracture repair. Design: Retrospective study. Setting: Level 1 trauma center. Patient Selection Criteria: A total of 965 patients 65 years or older who underwent surgical fixation for hip fractures (OTA/OA 31A, 31B and 31C) between 2018 and 2023. Outcome Measures and Comparisons: The primary outcome was mortality at 365 days after discharge. Secondary outcomes were mortality at 30 days and 90 days, length of stay (LOS) > 7 days, need for blood transfusion, and 30-day readmission. Statistical Methods: Multivariate Cox proportional hazards models assessed the association between antiplatelet use and mortality. For secondary outcomes, a Firth penalized logistic regression model was used, correcting for potential confounders. RESULTS: The use of antiplatelet medications perioperatively was not significantly associated with mortality at 365 days, with adjusted hazard ratio (aHR) of 1.17, 95% confidence interval (CI) [0.76, 1.79] or at 30 days and 90 days, with aHRs of 0.94, 95% CI [0.44, 2.00] and 1.03, 95% CI [0.54, 1.97], respectively. There was a higher odds of being readmitted within 30 days of hospital discharge and getting a transfusion, with adjusted odds ratios (aORs) of 1.83, 95% CI [1.12, 3.00] and 1.60, 95% CI [1.00, 2.56], respectively, whereas there was no significant association with length of stay greater than 7 days, with aOR of 0.84, 95% CI [0.56, 1.26]. Conclusion: These findings indicate that undergoing hip fracture repair while on antiplatelet medications does not appear to confer a higher risk of mortality but may be correlated to higher readmission or transfusion rates. Level of Evidence: Therapeutic Level III.

OTA International The Open Access Journal of Orthopaedic TraumaVol. 9(4)
Beth Israel Deaconess Medical Center (US)
Good health and well-being
Hip and Femur Fractures
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon